Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
Background: The roadmap approach is recommended to guide chronic hepatitis B treatment. We evaluated the cost-effectiveness of various treatment strategies in the global market. Methods: Lamivudine and telbivudine were tested in roadmap models with switch-to tenofovir if HBV was detectable at week 2...
Main Authors: | Lui, Y.Y.N., Tsoi, K.K.F., Wong, V.W.S., Kao, J.H., Hou, J.L., Teo, E.K., Mohamed, R., Piratvisuth, T., Han, K.H., Mihm, U., Wong, G.L.H., Chan, H.L.Y. |
---|---|
Format: | Article |
Published: |
International Medical Press
2010
|
Subjects: |
Similar Items
-
Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy
by: Teerha Piratvisuth, et al.
Published: (2016-04-01) -
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
by: Shui-Shan Lee, et al.
Published: (2020-05-01) -
Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
by: Tomoya Sano, et al.
Published: (2021-03-01) -
Roadmap on STIRAP applications
by: Bergmann, K, et al.
Published: (2019) -
Control of tungiasis in absence of a roadmap: grassroots and global approaches
by: Elson, L, et al.
Published: (2017)